Literature DB >> 2745978

Human peripheral lymphocyte growth regulation and response to phorbol esters is linked to synthesis and phosphorylation of the cytosolic protein, prosolin.

H L Cooper1, E McDuffie, R Braverman.   

Abstract

Prosolin is a major cytosolic protein (Mr 18400, isoelectric point 5.9) first reported in HL-60 promyelocytic leukemia cells. It is rapidly phosphorylated (15 to 30 min) in response to TPA treatment as an early event in a sequence that leads to cessation of cell proliferation and to differentiation of promyelocytes into monocytes. In our study we examined the expression of prosolin in human peripheral lymphocytes and investigated the effects of TPA treatment on prosolin phosphorylation and on lymphocyte proliferation. Prosolin was not expressed in resting PBL but was induced after 24 to 36 h of PHA stimulation, simultaneously with induction of DNA synthesis. In rapidly proliferating (IL-2 dependent) PBL prosolin was a major cytosolic component, comprising 0.5% of total cytosolic protein, of which approximately 28% was phosphorylated. Expression of prosolin decreased again when either mitogen-induced or IL-2-dependent proliferation diminished during extended periods in culture. Thus, expression of prosolin is correlated with periods when PBL are cycling through S-phase. TPA treatment of IL-2-dependent PBL at the peak of their growth caused phosphorylation of about two-thirds of preexisting unphosphorylated prosolin within 1 h. This was accompanied by cessation of cell proliferation, as indicated by measurements of TdR incorporation. Although TPA has well known mitogenic effects in lymphocytes during initial activation, this result shows that it exerts an antiproliferative effect in rapidly dividing PBL. It is suggested that increased phosphorylation of prosolin may be an initiating event in the antiproliferative response to TPA, which would occur only in proliferating lymphocytes expressing prosolin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2745978

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Stathmin interaction with a putative kinase and coiled-coil-forming protein domains.

Authors:  A Maucuer; J H Camonis; A Sobel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

2.  Stathmin levels in growth plate chondrocytes are modulated by vitamin D3 metabolites and transforming growth factor-beta1 and are associated with proliferation.

Authors:  T W Hummert; Z Schwartz; V L Sylvia; D D Dean; B D Boyan
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

3.  Stathmin is expressed by the proliferating hepatocytes during liver regeneration.

Authors:  D C Rowlands; R F Harrison; N A Jones; A Williams; S G Hubscher; G Brown
Journal:  Clin Mol Pathol       Date:  1995-04

4.  Stathmin-deficient mice develop an age-dependent axonopathy of the central and peripheral nervous systems.

Authors:  Wolfgang Liedtke; Elizabeth E Leman; Robert E W Fyffe; Cedric S Raine; Ulrich K Schubart
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

5.  Differential expression of Op18 phosphoprotein during human thymocyte maturation.

Authors:  J Gratiot-Deans; D Keim; J R Strahler; L A Turka; S Hanash
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

6.  Comparison of the levels of inositol metabolites in transformed haemopoietic cells and their normal counterparts.

Authors:  C M Bunce; P J French; P Allen; J C Mountford; B Moor; M F Greaves; R H Michell; G Brown
Journal:  Biochem J       Date:  1993-02-01       Impact factor: 3.857

7.  Expression of transfected stathmin cDNA reveals novel phosphorylated forms associated with developmental and functional cell regulation.

Authors:  V Doye; S Le Gouvello; T Dobransky; H Chneiweiss; L Beretta; A Sobel
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

8.  Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas.

Authors:  K Nylander; U Marklund; G Brattsand; M Gullberg; G Roos
Journal:  Histochem J       Date:  1995-02

9.  Molecular characterization of human stathmin expressed in Escherichia coli: site-directed mutagenesis of two phosphorylatable serines (Ser-25 and Ser-63).

Authors:  P A Curmi; A Maucuer; S Asselin; M Lecourtois; A Chaffotte; J M Schmitter; A Sobel
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

10.  Overexpression of the stathmin gene in a subset of human breast cancer.

Authors:  I Bièche; S Lachkar; V Becette; C Cifuentes-Diaz; A Sobel; R Lidereau; P A Curmi
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.